Literature DB >> 17994223

NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats.

Ian A Mendez1, Keith A Trujillo.   

Abstract

RATIONALE: N-Methyl-D: -aspartate (NMDA) receptors have an important role in different forms of behavioral and neural plasticity. Evidence suggests that these receptors may also be involved in plasticity arising from long-term treatment with different drugs of abuse, including tolerance, sensitization, and physical dependence. There is abundant evidence demonstrating that NMDA receptors are involved in tolerance to opiate-induced antinociception; however, the role of these receptors in sensitization to the locomotor effects of opiates is more controversial.
OBJECTIVE: The ability of NMDA receptor antagonists to modify the development of sensitization to the locomotor stimulant effect of three different opiates was examined. In selected studies, the ability of the antagonists to modify tolerance to the antinociceptive effects of the opiates was also examined.
MATERIALS AND METHODS: Adult male Sprague-Dawley rats were used to assess the effects of NMDA receptor antagonists (MK-801, memantine or LY235959) on tolerance and sensitization to three opiates: morphine, methadone, or buprenorphine. It was predicted that low, selective doses of the antagonists would inhibit the development of opiate tolerance and sensitization.
RESULTS: Consistent with our predictions, the noncompetitive NMDA receptor antagonists MK-801 and memantine and the competitive NMDA receptor antagonist LY235959 inhibited the development of sensitization to the locomotor stimulant effect of morphine. Additionally, MK-801 inhibited the development of tolerance and sensitization to methadone and buprenorphine in a similar manner.
CONCLUSIONS: The results, together with previous research, suggest that NMDA receptors are broadly involved in opiate-induced plasticity, including the development of opiate tolerance and sensitization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994223     DOI: 10.1007/s00213-007-0984-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

1.  Effects of the non-competitive NMDA-receptor antagonist memantine on morphine- and cocaine-induced potentiation of lateral hypothalamic brain stimulation reward.

Authors:  T M Tzchentke; W J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  2000-04       Impact factor: 4.530

2.  MK-801 prevents the development of behavioral sensitization during repeated morphine administration.

Authors:  M Jeziorski; F J White; M E Wolf
Journal:  Synapse       Date:  1994-02       Impact factor: 2.562

Review 3.  The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction.

Authors:  B H Herman; F Vocci; P Bridge
Journal:  Neuropsychopharmacology       Date:  1995-12       Impact factor: 7.853

4.  Procedural examination of behavioural sensitisation to morphine: lack of blockade by MK-801, occurrence of sensitised sniffing, and evidence for cross-sensitisation between morphine and MK-801.

Authors:  T.M. Tzschentke; W.J. Schmidt
Journal:  Behav Pharmacol       Date:  1996-03       Impact factor: 2.293

5.  Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test.

Authors:  P Popik; E Kozela
Journal:  Pol J Pharmacol       Date:  1999 May-Jun

Review 6.  Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review).

Authors:  R F Bell; J B Dahl; R A Moore; E Kalso
Journal:  Acta Anaesthesiol Scand       Date:  2005-11       Impact factor: 2.105

7.  An antisense oligonucleotide to the N-methyl-D-aspartate (NMDA) subunit NMDAR1 attenuates NMDA-induced nociception, hyperalgesia, and morphine tolerance.

Authors:  Naohito Shimoyama; Megumi Shimoyama; Antonia M Davis; Daniel T Monaghan; Charles E Inturrisi
Journal:  J Pharmacol Exp Ther       Date:  2004-09-23       Impact factor: 4.030

8.  The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat.

Authors:  S Ben-Eliyahu; P Marek; A L Vaccarino; J S Mogil; W F Sternberg; J C Liebeskind
Journal:  Brain Res       Date:  1992-03-20       Impact factor: 3.252

9.  Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614.

Authors:  P J Tiseo; C E Inturrisi
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

10.  MK-801 disrupts the expression but not the development of bromocriptine sensitization: a state-dependency interpretation.

Authors:  W A Carlezon; A Mendrek; R A Wise
Journal:  Synapse       Date:  1995-05       Impact factor: 2.562

View more
  15 in total

1.  Dopaminergic modulation of risky decision-making.

Authors:  Nicholas W Simon; Karienn S Montgomery; Blanca S Beas; Marci R Mitchell; Candi L LaSarge; Ian A Mendez; Cristina Bañuelos; Colin M Vokes; Aaron B Taylor; Rebecca P Haberman; Jennifer L Bizon; Barry Setlow
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

2.  Chronic Opioid Therapy Modifies QST Changes After Ketamine Infusion in Chronic Pain Patients.

Authors:  Dermot P Maher; Yi Zhang; Shihab Ahmed; Tina Doshi; Charlene Malarick; Kristin Stabach; Jianren Mao; Lucy Chen
Journal:  J Pain       Date:  2017-08-10       Impact factor: 5.820

3.  Inhibition of GTP cyclohydrolase reduces cancer pain in mice and enhances analgesic effects of morphine.

Authors:  Geethanjali Pickert; Thekla Myrczek; Steven Rückert; Andreas Weigert; Annett Häussler; Nerea Ferreirós; Bernhard Brüne; Jörn Lötsch; Irmgard Tegeder
Journal:  J Mol Med (Berl)       Date:  2012-06-17       Impact factor: 4.599

4.  Opioid antinociception, tolerance and dependence: interactions with the N-methyl-D-aspartate system in mice.

Authors:  Linda A Dykstra; Bradford D Fischer; Rebecca E Balter; Fredrick E Henry; Karl T Schmidt; Laurence L Miller
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

5.  Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects.

Authors:  Bradford D Fischer; Sara J Ward; Fredrick E Henry; Linda A Dykstra
Journal:  Neuropharmacology       Date:  2009-08-21       Impact factor: 5.250

Review 6.  Methadone: a new old drug with promises and pitfalls.

Authors:  Jodie A Trafton; Abhinav Ramani
Journal:  Curr Pain Headache Rep       Date:  2009-02

7.  Role of D₁/D₂ dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats.

Authors:  Ercan Ozdemir; Ihsan Bagcivan; Sinan Gursoy
Journal:  Bosn J Basic Med Sci       Date:  2013-05       Impact factor: 3.363

8.  Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.

Authors:  Gerardo Gonzalez; Gregory DiGirolamo; Mauricio Romero-Gonzalez; David Smelson; Douglas Ziedonis; Monika Kolodziej
Journal:  Drug Alcohol Depend       Date:  2015-09-30       Impact factor: 4.492

9.  Effects of Dextromethorphan on reducing methadone dosage in opium addicts undergoing methadone maintenance therapy: A double blind randomized clinical trial.

Authors:  Mehrdad Salehi; Ali Zargar; Mohammad Arash Ramezani
Journal:  J Res Med Sci       Date:  2011-10       Impact factor: 1.852

10.  Distinct profiles of anxiety and dysphoria during spontaneous withdrawal from acute morphine exposure.

Authors:  Patrick E Rothwell; Mark J Thomas; Jonathan C Gewirtz
Journal:  Neuropsychopharmacology       Date:  2009-06-03       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.